Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Multiple Key Leadership Appointments, Including Warner Biddle as CEO, Bringing Clinical, Commercial and Strategic Expertise in Cell Therapy Continuing to Advance Broad KYSA Clinical Development Program: Presented Clinical Data Highlighting Potential for KYV-101 in SPS, MG and MS at ECTRIMS and Plan to Share Updated Clinical Data in LN at Company Symposium at ACR Convergence 2024Strong Financial Position; Ended the Quarter With $321.6 Million in Cash, Cash Equivalents and Marketable SecuritiesEMERYVILLE, Cal ...